Dompé pursues ambitions with Anabasis buy
This article was originally published in Scrip
Dompé farmaceutici's decision to acquire the 51% of Anabasis Pharma it does not already own is wholly consistent with its ambition to become a fully integrated international biotech company with a robust clinical pipeline. Starting in 2007, with an empty clinical pipeline and a vulnerable reliance on the Italian primary care market, the private Italian pharmaceutical company, has been reinventing itself as an international research-powered biopharmaceutical company.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.